Condition: Prostate Cancer · Sponsor: German Oncology Center, Cyprus
A prospective, single-arm phase II study is the individualization of RT for patients with high-risk localized PCa based on multimodal artificial intelligence (MMAI). All patients will receive the current standard of care: (i) a dose escalation to the prostate via HDR brachytherapy, (ii) two years of ADT and (iii) whole-pelvis UHF-RT (5 fractions).
This description comes directly from the study's public registry record.
Elena Pallari, PhD · 0035725028690 · elena.pallari@goc.com.cy
Kristis Vevis, PhD · 0035725208159 · kristis.vevis@goc.com.cy
Always discuss trial participation with your own doctor first.
| German Oncology Center | Limassol, Cyprus | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06582446